Aimee Lenar Sells 36,827 Shares of Bausch Health Cos (NYSE:BHC) Stock

Bausch Health Cos Inc. (NYSE:BHC) insider Aimee Lenar sold 36,827 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the transaction, the insider directly owned 334,853 shares in the company, valued at approximately $2,354,016.59. This represents a 9.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Stock Performance

NYSE BHC opened at $6.42 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 54.68. The company has a market capitalization of $2.40 billion, a P/E ratio of -2.17 and a beta of 0.38. Bausch Health Cos Inc. has a 12-month low of $4.33 and a 12-month high of $8.00. The firm has a 50-day moving average price of $5.36 and a two-hundred day moving average price of $5.46.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. Analysts anticipate that Bausch Health Cos Inc. will post 4.35 earnings per share for the current year.

Institutional Investors Weigh In On Bausch Health Cos

Several large investors have recently added to or reduced their stakes in BHC. Public Employees Retirement System of Ohio bought a new stake in Bausch Health Cos in the second quarter valued at $2,565,000. Bank of America Corp DE bought a new position in shares of Bausch Health Cos during the 2nd quarter worth about $2,816,000. Paulson & CO. Inc. bought a new position in shares of Bausch Health Cos during the 2nd quarter worth about $361,151,000. Man Group plc acquired a new stake in shares of Bausch Health Cos in the 2nd quarter valued at about $7,157,000. Finally, Biglari Capital CORP. acquired a new stake in shares of Bausch Health Cos in the 2nd quarter valued at about $202,475,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on BHC. Royal Bank Of Canada lowered their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Zacks Research lowered Bausch Health Cos from a “hold” rating to a “strong sell” rating in a research note on Friday, July 24th. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Weiss Ratings raised Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Finally, Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Five investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Bausch Health Cos currently has a consensus rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos News Summary

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Upgraded to Buy: BHC was raised to Zacks Rank #2 (Buy), reflecting improved expectations for the company’s earnings and potentially supporting further near-term gains. Bausch Upgraded to Buy
• Positive Sentiment: Higher earnings estimates: Zacks analysts raised forecasts across multiple periods, including FY2027 EPS to $3.84 from $3.59 and FY2028 EPS to $3.04 from $3.02. Estimates for several 2027 and 2028 quarters were also increased, reinforcing the view that earnings momentum could drive the stock higher. Rising Earnings Estimates
• Positive Sentiment: Bausch + Lomb growth thesis: An investment analysis highlighted 9% year-over-year revenue growth in the second quarter, margin expansion and strong operating cash flow. Growth in premium intraocular lenses and branded pharmaceuticals could improve product mix, EBITDA and cash generation while supporting deleveraging. Bausch Plus Lomb Analysis
• Neutral Sentiment: Despite the estimate increases, Zacks Research continues to rate BHC Strong Sell. The broader analyst consensus is “Reduce,” with an average price target of $8, indicating limited upside relative to current trading levels.
• Negative Sentiment: Insider Aimee Lenar sold 36,827 shares worth approximately $258,894 under a pre-arranged Rule 10b5-1 plan. Although the scheduled nature reduces its significance, the transaction cut her direct holding by 9.91%. Insider Share Sale

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.